Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine
Top Cited Papers
Open Access
- 12 December 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Genome Editing
- Vol. 6, 1509924
Abstract
CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated proteins) has undergone marked advancements since its discovery as an adaptive immune system in bacteria and archaea, emerged as a potent gene-editing tool after the successful engineering of its synthetic guide RNA (sgRNA) toward the targeting of specific DNA sequences with high accuracy. Besides its DNA editing ability, further-developed Cas variants can also edit the epigenome, rendering the CRISPR-Cas system a versatile tool for genome and epigenome manipulation and a pioneering force in precision medicine. This review explores the latest advancements in CRISPR-Cas technology and its therapeutic and biomedical applications, highlighting its transformative impact on precision medicine. Moreover, the current status of CRISPR therapeutics in clinical trials is discussed. Finally, we address the persisting challenges and prospects of CRISPR-Cas technology.Keywords
This publication has 319 references indexed in Scilit:
- Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome EditingSmall Science, 2024
- Targets of tumor microenvironment for potential drug developmentMedComm – Oncology, 2024
- Nanotechnology‐based CRISPR/Cas9 delivery system for genome editing in cancer treatmentMedcomm – Biomaterials and Applications, 2024
- Role of tumor microenvironment in cancer progression and therapeutic strategyCancer Medicine, 2023
- CRISPR/Cas9‐HPV‐liposome enhances antitumor immunity and treatment of HPV infection‐associated cervical cancerJournal of Medical Virology, 2022
- Antitumor efficacy of CRISPR/Cas9–engineered ICP6 mutant herpes simplex viruses in a mouse xenograft model for lung adenocarcinomaJournal of Medical Virology, 2022
- Genome Editing, Ethics, and PoliticsAMA Journal of Ethics, 2019
- Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcomaJournal of Orthopaedic Research, 2019
- Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform†Hepatology, 2017
- Error‐Prone Repair of DNA Double‐Strand BreaksJournal of Cellular Physiology, 2015